Shandong First Medical University
山东第一医科大学
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 13 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 2
- Research papers it led
- 13
- Trials it led
- 2
- Share of China's trials
- 0.3%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
- A Stacked Multimodality Model Based on Functional MRI Features and Deep Learning Radiomics for Predicting the Early Response to Radiotherapy in Nasopharyngeal Carcinoma.
- Pretreatment multiparametric MRI radiomics-integrated clinical hematological biomarkers can predict early rapid metastasis in patients with nasopharyngeal carcinoma.
- Association of Socioeconomic Disparities With Nasopharyngeal Carcinoma Survival in an Endemic Area, China.
- Nasopharyngeal carcinoma misdiagnosed as pituitary tumor with multiple cranial neuropathies.
Trials on ClinicalTrials.gov4
- Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
- Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
- A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
- Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 104 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 3
- Research papers it led
- 104
- Trials it led
- 10
- Share of China's trials
- 1.8%
- Share of the world's papers
- 2.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.
- Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial.
- Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.
- Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures.
- Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial.
Trials on ClinicalTrials.gov6
- Neoadjuvant QL1706 Therapy for ESCC
- Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
- Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Hepatocellular carcinoma
肝细胞癌Led 191 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 4
- Research papers it led
- 191
- Trials it led
- 13
- Share of China's trials
- 0.9%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.
- Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
- Radiomic Model Based on Multisequence MRI to Preoperative Predict Ki-67 Expression in Hepatocellular Carcinoma.
- Predictive model development and validation of functional liver imaging score for prognosis of patients with hepatocellular carcinoma after surgical resection: a multicenter study.
- Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching compar
Trials on ClinicalTrials.gov6
- Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
- BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
- Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
- Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
- First in Human Study of SIM0610 in Solid Tumors
- MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
Stomach cancer
胃癌Led 153 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 1
- Research papers it led
- 153
- Trials it led
- 6
- Share of China's trials
- 0.4%
- Share of the world's papers
- 0.7%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer.
- Effects of perioperative low-dose naloxone on the immune system in patients undergoing laparoscopic-assisted total gastrectomy: a randomized controlled trial.
- Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
- Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.
- Simple Postoperative Markers for Early Identification of Low-Risk Patients After Gastric or Colorectal Cancer Surgery: A Retrospective Cohort Study.
Trials on ClinicalTrials.gov6
- Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
Hepatoblastoma
肝母细胞瘤Led 4 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.6%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Density of tertiary lymphoid structures predict clinical outcome in hepatoblastoma.
- Cancer in 22q11.2 deletion syndrome: A case report and literature review.
- Key Modulation of ROS and HSP for Effective Therapy Against Hypoxic Tumor with Multifunctional Nanosystem.
- SOX7 modulates the progression of hepatoblastoma through the regulation of Wnt/β-catenin signaling pathway.
Trials on ClinicalTrials.gov1
Retinoblastoma
视网膜母细胞瘤Led 0 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 0
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.0%
Trials on ClinicalTrials.gov1
Osteosarcoma
骨肉瘤Led 20 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 20
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.
- The osteosarcoma immune microenvironment in progression: PLEK as a prognostic biomarker and therapeutic target.
- Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi-Omics Analysis.
- miR-1343-3p, mediated by LncRNA ASMTL-AS1, induces ferroptosis in osteosarcoma progression by targeting TYRO3.
- Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 5 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Development of a multi-phase CT-based radiomics model to differentiate heterotopic pancreas from gastrointestinal stromal tumor.
- Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection.
- Succinate dehydrogenase deficient gastrointestinal stromal tumor in a three month old boy with a fatal clinical course: a case report and review of literature.
- Clinicopathological characteristics and longterm survival of patients with synchronous multiple primary gastrointestinal stromal tumors: A propensity score matching analysis.
- Association between R1 resection and oncological outcome in resectable gastrointestinal stromal tumors without tumor rupture: A systematic review and meta-analysis.
Trials on ClinicalTrials.gov1
Neuroblastoma
神经母细胞瘤Led 10 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Diagnostic value of diffusion-weighted magnetic resonance imaging in differentiating benign and malignant fetal adrenal tumors.
- Pathological validation of 18F-AlF-NOTA-octreotide PET/CT for neuroblastoma.
- A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China.
- Feasibility of Single Time Point Dosimetry Application in 177 Lu-DOTATATE/DOTATOC-treated Pediatric Neuroblastoma.
- Radiation Exposure to Patients and Others During Therapy for Pediatric Neuroblastoma With Lu-177-DOTATATE.
Multiple myeloma
多发性骨髓瘤Led 16 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 0
- Research papers it led
- 16
- Trials it led
- 2
- Share of China's trials
- 0.4%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Multiple myeloma in a man with breast cancer: A case report and literature review.
- The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).
- Whole-genome sequencing reveals cellular origin of concomitant chronic lymphocytic leukemia and multiple myeloma: a case report.
- Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study.
- An MRI-based radiomics nomogram for differentiating spinal metastases from multiple myeloma.
Trials on ClinicalTrials.gov6
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Aplastic anaemia
再生障碍性贫血Led 6 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Comparative longitudinal analysis of pulmonary function post-pediatric Allo-HSCT: benign vs. malignant diseases and early predictors.
- The ratio of bone marrow myeloid progenitor cell proportion to mature lymphocytes proportion can effectively differentiate aplastic anemia and hypoplastic myelodysplastic syndrome and evaluate the quality of bone marrow
- Novel compound heterozygous variants in FANCI cause premature ovarian insufficiency.
- Pan-cancer analysis of the tumorigenic role of Fanconi anemia complementation group D2 (FANCD2) in human tumors.
- Identification of novel mutations in patients with Diamond-Blackfan anemia and literature review of RPS10 and RPS26 mutations.
Trials on ClinicalTrials.gov1
Haemophilia A
血友病 ALed 3 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 1
- Share of China's trials
- 1.2%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Application of enhanced recovery after surgery in total knee arthroplasty in patients with haemophilia A: A pilot study.
- Retrospective analysis of clinical data from 171 low-income patients with hemophilia in Shandong Province.
- Influencing factors of the outcome of patients with haemophilia after knee replacement-a retrospective study.
Trials on ClinicalTrials.gov6
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
Fanconi anaemia
范可尼贫血Led 3 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
Trials on ClinicalTrials.gov1
Myasthenia gravis
重症肌无力Led 17 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 0
- Research papers it led
- 17
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review.
- Efgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review.
- Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center.
- Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
- Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application.
Trials on ClinicalTrials.gov3
Moyamoya disease
烟雾病Led 5 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Multi-parameter MRI-Based Machine Learning Model to Evaluate the Efficacy of STA-MCA Bypass Surgery for Moyamoya Disease: A Pilot Study.
- Can combined high-resolution vessel wall imaging and multiple post-labeling delay 3D pseudo-continuous arterial spin labeling differentiate moyamoya disease from atherosclerotic moyamoya syndrome?
- Knockdown the moyamoya disease susceptibility gene, RNF213, upregulates the expression of basic fibroblast growth factor and matrix metalloproteinase-9 in bone marrow derived mesenchymal stem cells.
- Bradykinin-bradykinin receptor (B1R) signalling is involved in the blood-brain barrier disruption in moyamoya disease.
- The emerging role of E3 ubiquitin ligase RNF213 as an antimicrobial host determinant.
Wilson disease
肝豆状核变性(Wilson 病)Led 2 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.5%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 13 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 13
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis.
- Effectiveness of Anti-CD20 B cells depleting therapy versus conventional treatment in severe Anti-N-methyl-d-aspartate receptor encephalitis: A real-world multi-center prospective cohort study.
- Low-dose rituximab for the treatment of anti-NMDAR encephalitis in children: a case series study.
- Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review.
- Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China.
Takayasu arteritis
大动脉炎Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (24.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 5 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial.
- Targeting E3 ubiquitin ligases: a new frontier in idiopathic pulmonary fibrosis treatment.
- Prediction model of mitochondrial energy metabolism related genes in idiopathic pulmonary fibrosis and its correlation with immune microenvironment.
- Mendelian randomisation highlights hypothyroidism as a causal determinant of idiopathic pulmonary fibrosis.
- miR-21 Exerts Anti-proliferative and Pro-apoptotic Effects in LPS-induced WI-38 Cells via Directly Targeting TIMP3.
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.05%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- DTI changes of brachial plexus nerve roots in amyotrophic lateral sclerosis and their correlation with electrophysiology.
- lncRNA NEAT1: Key player in neurodegenerative diseases.
- Characterization of Fasciculation Potentials (FPs) in Amyotrophic Lateral Sclerosis (ALS) and Peripheral Nerve Hyperexcitability Syndromes (PNH).
Behçet disease
白塞病Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet's uveitis: A systematic review and meta-analysis.
- Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.
- Association Between Interleukin 35 Gene Single Nucleotide Polymorphisms and the Uveitis Immune Status in a Chinese Han Population.
IgA nephropathy
IgA 肾病Led 4 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Coexisting nutcracker phenomenon and superior mesenteric artery syndrome in a patient with IgA nephropathy: A case report.
- BAFF in autoimmune kidney diseases: pathogenic pathways, biomarker potential, and therapeutic horizons.
- A simple nomogram for assessing the risk of IgA vasculitis nephritis in IgA vasculitis Asian pediatric patients.
- Associations of left renal vein entrapment with IgA nephropathy and Henoch-Schönlein purpura nephritis.
Trials on ClinicalTrials.gov4
Osteogenesis imperfecta
成骨不全症Led 7 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Home care needs assessment among caregivers of children and adolescents with osteogenesis imperfecta: a cross-sectional study.
- Risk perception for fractures and its related factors among family caregivers of underage patients with osteogenesis imperfecta in China: A cross-sectional study.
- Generation of a non-integrated induced pluripotent stem cell line from urine cells of a Chinese osteogenesis imperfecta type I patient.
- Genotype-Phenotype Relationship and Follow-up Analysis of a Chinese Cohort With Osteogenesis Imperfecta.
- Endoplasmic reticulum stress and autophagy as potential therapeutic targets in SERPINF1 mutation-induced type VI osteogenesis imperfecta.
Primary biliary cholangitis
原发性胆汁性胆管炎Led 3 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Proteomics identifies complement protein signatures in patients with primary biliary cholangitis.
- The causal effect of bioavailable testosterone on primary biliary cholangitis in female patients: A Bidirectional Mendelian randomization analysis.
- Comparative analysis of clinical diagnosis and ultrasonic diagnosis between primary biliary cirrhosis and viral hepatitis cirrhosis.
Hirschsprung disease
先天性巨结肠Led 3 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.0%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Proteomic Analysis Provides a New Sight Into the CRABP1 Expression in the Pathogenesis of Hirschsprung Disease.
- Aberrant expression of LINC00346 regulates cell migration and proliferation via competitively binding to miRNA-148a-3p/Dnmt1 in Hirschsprung's disease.
- MiR-195-5p inhibits proliferation and invasion of nerve cells in Hirschsprung disease by targeting GFRA4.